[Skip to Content]
[Skip to Content Landing]
Other Articles
April 28, 1962

The Use of Amphotericin B in Man

Author Affiliations

New Haven, Conn.; Boston

From the U.S. Department of Health, Education and Welfare, Public Health Service, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Laboratory of Clinical Investigation, Bethesda, Md.

JAMA. 1962;180(4):269-272. doi:10.1001/jama.1962.03050170001001

Amphotericin B is the only broad-spectrum antifungal agent currently available for the treatment of systemic mycotic infections in man. Administered intravenously, it has been effective in the treatment of patients with histoplasmosis, North American blastomycosis, coccidiomycosis, cryptococcosis, and specific Candida infections. In addition, isolated cases of South American blastomycosis, aspergillosis, sporotrichosis, mucormycosis, and chromoblastomycosis have responded favorably. Intrathecal administration is frequently indicated in systemic fungal infections involving the central nervous system. The reversible side effects of chills, fever, nausea, vomiting, hypokalemia, anemia, and azotemia warrant necessary precautions during the administration of this agent. Simple safeguards can effectively control these manifestations and so enhance the usefulness of this potent antifungal antibiotic when used via the intravenous and intrathecal routes.